Loading stock data…
TYRA
$25.94-0.81 (-3.03%)
After Hours$25.25-0.69 (-2.66%)· Last close Jun 9
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tyra Biosciences, Inc. in the Healthcare sector is trading at $25.94. Wall Street consensus targets $51.15 (11 analysts), implying a +97.2% move over the next 12 months. The stock is currently 36% below its 52-week high of $40.65, remaining 1.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +97.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 17) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$25.94
Potential Downside
0%
Whystock Fair Value$25.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$51.15+97.2%
Range$37.00 – $59.62
Fundamentals
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.83%
Volume
Today's trading volume
1.42M
Recent News
Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds. On May 19, Wolfe Research initiated Tyra Biosciences, Inc. (NASDAQ:TYRA) with a Peer Perform rating and no price target. The analyst stated dabogratinib could “achieve the CR bar for LR IR NMIBC” while remaining “on […]
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Momentum
Why Tyra Biosciences Stock Is On Investors’ Radar Tyra Biosciences (TYRA) has drawn attention after a period of strong share price moves, with the stock up 3.8% over the past day, 10% over the past week and 2.6% over the past month. See our latest analysis for Tyra Biosciences. That recent 3.8% daily move comes on top of a 29.3% 90 day share price return and a very large 267% 1 year total shareholder return. Together, these figures point to strong, sustained momentum rather than a short lived...
Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Tyra Biosciences, Inc. is one of the best biotech stocks on this list. TheFly reported on April 15 that Guggenheim Securities initiated coverage of TYRA with a Buy rating and set a price target of $54. The firm highlighted […]
A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress
Tyra Biosciences (TYRA) has drawn fresh attention after arranging a US$126 million stock sale to a large investment firm, together with progress on late stage trials and recent leadership changes. See our latest analysis for Tyra Biosciences. Those headlines have arrived during a strong run for the stock, with a 47.85% year to date share price return and a very large 1 year total shareholder return that points to strong momentum rather than fading enthusiasm. If Tyra’s surge has you thinking...